Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.67 |
| ▸ | KDR | P35968 | 19/20 | 0.67 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | FPR1 | P21462 | 1/20 | 0.54 |
| ▸ | FPR3 | P25089 | 1/20 | 0.54 |
| ▸ | GPR183 | P32249 | 1/20 | 0.54 |
| ▸ | SMO | Q99835 | 1/20 | 0.54 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3565980 | 0.88 | MET (0.80) | METKDR | |
| SCHEMBL3574961 | 0.86 | MET (0.80) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL3564997 | 0.85 | MET (0.79) | METKDR | |
| SCHEMBL3562595 | 0.85 | MET (0.64) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL3575507 | 0.84 | MET (0.81) | METKDR | |
| SCHEMBL3572247 | 0.83 | MET (0.72) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL3570382 | 0.83 | MET (0.81) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL3566054 | 0.82 | MET (0.70) | METKDR | |
| SCHEMBL3568961 | 0.82 | MET (0.77) | METKDR | |
| SCHEMBL3621481 | 0.82 | MET (0.82) | METKDRAURKAFPR1FPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781664-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2013-09-04 | — | — | EP | disclosed |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | METHYLGENE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7772247-B2 | Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor | METHYLGENE INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. (CA) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | MET 2/4885KDR 4/4885AURKA 1837/4885 |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | HGF, MET, FLT1 | MET 2/4885KDR 4/4885AURKA 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.